Dizopiramid

Izvor: Wikipedija
Prijeđi na navigaciju Prijeđi na pretragu
Dizopiramid
(IUPAC) ime
(RS)-4-(diizopropilamino)-2-fenil-2-(piridin-2-il)butanamid
Klinički podaci
Robne marke Norpace
AHFS/Drugs.com Monografija
MedlinePlus a682408
Identifikatori
CAS broj 3737-09-5
ATC kod C01BA03
PubChem[1][2] 3114
DrugBank DB00280
ChemSpider[3] 3002
UNII GFO928U8MQ DaY
KEGG[4] D00303 DaY
ChEBI CHEBI:4657 DaY
ChEMBL[5] CHEMBL517 DaY
Hemijski podaci
Formula C21H29N3O 
Mol. masa 339,475 g/mol
SMILES eMolekuli & PubHem
Farmakokinetički podaci
Bioraspoloživost Visoka
Vezivanje za proteine plazme 50% do 65%
Metabolizam Hepatički (CYP3A4-posredovano)
Poluvreme eliminacije 6,7 sati (4 do 10 sati)
Izlučivanje Renalno (80%)
Farmakoinformacioni podaci
Trudnoća B2(AU) C(US)
Pravni status POM (UK) ℞-only (SAD)
Način primene Oralno, intravenozno

Dizopiramid (INN, Norpace, Rythmodan) antiaritmički je lek, koji se koristi za tretiranje ventrikularne tahikardije.[6] On je blokator natrijumovog kanala i stoga se klasifikuje u klasu 1a anti-aritmičkih agenasa.[7][8] Dizopiramid ima negativno inotropno dejstvo na ventrikularni miokard. On znatno umanjuje kontraktilnost.[9][10] Dizopiramid takođe ima antiholinergički uticaj na srce, što uzrokuje mnoštvo nuspojava. Dizopiramid je dostupan u oralnoj i intravenoznoj formi, i ima nizak stepen toksičnosti.[10]

Hemija[uredi | uredi kod]

Dizopiramid se može sintetisati iz benzil cijanida i 2-bromopiridina:[11]

Reference[uredi | uredi kod]

  1. ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.  edit
  4. ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. 
  5. ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  6. ↑ Guyton, Arthur C., Hall, John E. (2006). Textbook of Medical Physiology (11th ed.). Philadelphia: Elsevier Saunders
  7. ↑ Rizos, I. I., et al. "Effects of Intravenous Disopyramide and Quinidine on Normal Myocardium and on the Characteristics of Arrhythmias: Intraindividual Comparison in Patients with Sustained Ventricular Tachycardia." European heart journal 8.2 (1987): 154-63. Biological Sciences. Web. 10 Feb. 2012
  8. ↑ Kim, S. Y. SY, and N. L. NL Benowitz. "Poisoning due to Class IA Antiarrhythmic Drugs. Quinidine, Procainamide and Disopyramide." Drug safety : an international journal of medical toxicology and drug experience 5.6 (1990): 393-420. Biological Sciences; Environmental Science and Pollution Management. Web. 12 Feb. 2012.
  9. ↑ Levites, R. R., and G. J. GJ Anderson. "Electrophysiological Effects of Disopyramide Phosphate during Experimental Myocardial Ischemia." American Heart Journal 98.3 (1979): 339-44. Biological Sciences. Web. 15 Feb. 2012.
  10. ↑ 10,0 10,1 Mathur, P. P. PP. "Cardiovascular Effects of a Newer Antiarrhythmic Agent, Disopyramide Phosphate." American Heart Journal 84.6 (1972): 764-70. Biological Sciences; Environmental Science and Pollution Management. Web. 15 Feb. 2012
  11. ↑ U.S. Patent 3.225.054

Literatura[uredi | uredi kod]

  1. Guyton, Arthur C., Hall, John E. (2006). Textbook of Medical Physiology (11th ed.). Philadelphia: Elsevier Saunders.
  2. Rizos, I. I., et al. "Effects of Intravenous Disopyramide and Quinidine on Normal Myocardium and on the Characteristics of Arrhythmias: Intraindividual Comparison in Patients with Sustained Ventricular Tachycardia." European heart journal 8.2 (1987): 154-63. Biological Sciences. Web. 10 Feb. 2012.
  3. Katzung, Bertram G., Masters, Susan B., Trevor, Anthony J. (2009). Basic and Clinical Pharmacology (11th ed.). New York: McGraw Hill
  4. Levites, R. R., and G. J. GJ Anderson. "Electrophysiological Effects of Disopyramide Phosphate during Experimental Myocardial Ischemia." American Heart Journal 98.3 (1979): 339-44. Biological Sciences. Web. 15 Feb. 2012.
  5. Hulting J, Rosenhamer G: Hemodynamic and electrocardiographic effects of disopyramide in patients with ventricular arrhythmia. Acta Med Scand 199:41-51, 1976.
  6. Mathur, P. P. PP. "Cardiovascular Effects of a Newer Antiarrhythmic Agent, Disopyramide Phosphate." American Heart Journal 84.6 (1972): 764-70. Biological Sciences; Environmental Science and Pollution Management. Web. 15 Feb. 2012.
  7. Kim, S. Y. SY, and N. L. NL Benowitz. "Poisoning due to Class IA Antiarrhythmic Drugs. Quinidine, Procainamide and Disopyramide." Drug safety : an international journal of medical toxicology and drug experience 5.6 (1990): 393-420. Biological Sciences; Environmental Science and Pollution Management. Web. 12 Feb. 2012.

Spoljašnje veze[uredi | uredi kod]

Portal Medicina
Portal Hemija
Izvor: https://sh.wikipedia.org/w/index.php?title=Dizopiramid&oldid=41487372